Creative Planning trimmed its position in Crispr Therapeutics AG (NASDAQ:CRSP) by 3.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,376 shares of the company’s stock after selling 559 shares during the quarter. Creative Planning’s holdings in Crispr Therapeutics were worth $589,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. BSW Wealth Partners acquired a new stake in Crispr Therapeutics in the second quarter valued at about $39,000. Balyasny Asset Management LLC bought a new position in Crispr Therapeutics in the second quarter valued at about $5,165,000. BNP Paribas Arbitrage SA bought a new position in Crispr Therapeutics in the second quarter valued at about $41,000. Bank of New York Mellon Corp raised its position in Crispr Therapeutics by 116.5% in the second quarter. Bank of New York Mellon Corp now owns 33,091 shares of the company’s stock valued at $1,559,000 after purchasing an additional 17,810 shares during the last quarter. Finally, ARK Investment Management LLC raised its position in Crispr Therapeutics by 34.7% in the second quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after purchasing an additional 701,332 shares during the last quarter. 49.81% of the stock is currently owned by hedge funds and other institutional investors.
Several equities analysts have commented on CRSP shares. TheStreet upgraded Crispr Therapeutics from a “d” rating to a “c” rating in a research report on Monday, October 28th. ValuEngine upgraded Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a research report on Tuesday, November 19th. Roth Capital raised their price objective on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. Finally, Oppenheimer raised their price objective on Crispr Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a research report on Monday. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $69.54.
Shares of Crispr Therapeutics stock opened at $68.11 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.32 and a current ratio of 8.32. Crispr Therapeutics AG has a 52 week low of $22.22 and a 52 week high of $74.00. The stock has a 50 day moving average price of $49.29 and a two-hundred day moving average price of $46.08. The stock has a market capitalization of $3.63 billion, a PE ratio of -19.80 and a beta of 3.15.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. Research analysts forecast that Crispr Therapeutics AG will post 0.65 EPS for the current year.
In related news, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the sale, the president now directly owns 33,618 shares in the company, valued at $2,353,260. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the sale, the director now owns 7,500 shares in the company, valued at $390,000. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 56,118 shares of company stock worth $3,620,760. 21.40% of the stock is owned by insiders.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Further Reading: Discover Your Risk Tolerance
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.